Suggested Readings

2020 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease.

Budd Haeberlein S, von Hehn C, Tian Y, et al. Presented at: 12th Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.

Neuroinflammation in Alzheimer’s disease: current evidence and future directions.

Calsolaro V, Edison P. Alzheimers Dement. 2016;12(6):719-732.

Alzheimer’s disease prevention: from risk factors to early intervention.

Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimers Res Ther. 2017;9(1):71.

A practical algorithm for managing Alzheimer’s disease: what, when, and why?

Cummings JL, Isaacson RS, Schmitt FA, Velting DM. Ann Clin Transl Neurol. 2015;2(3):307-323.

Revising the definition of Alzheimer’s disease: a new lexicon.

Dubois B, Feldman HH, Jacova C, et al. Lancet Neurol. 2010;9(11):1118-1127.

Update on Alzheimer’s disease therapy and prevention strategies.

Graham WV, Bonito-Oliva A, Sakmar TP. Annu Rev Med. 2017;68:413-430.

Alzheimer’s disease: the amyloid cascade hypothesis.

Hardy JA, Higgins GA. Science. 1992;256(5054):184-185.

Alzheimer’s disease: the amyloid hypothesis on trial.

Harrison JR, Owen MJ. Br J Psychiatry. 2016;208(1):1-3.

Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers.

Jack CR Jr, Knopman DS, Jagust WJ, et al. Lancet Neurol. 2013;12(2):207-216.

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.

Molecular and cellular basis of neurodegeneration in Alzheimer’s disease.

Jeong S. Mol Cells. 2017;40(9):613-620.

Cognitive symptoms of Alzheimer’s disease: clinical management and prevention.

Joe E, Ringman JM. BMJ. 2019;367:l6217.

The diagnosis and management of mild cognitive impairment: a clinical review.

Langa KM, Levine DA. JAMA. 2014;312(23):2551-2561.

Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older.

Larson EB, Wang L, Bowen JD, et al. Ann Intern Med. 2006;144(2):73-81.

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Panza F, Lozupone M, Logroscino G, Imbimbo BP. Nat Rev Neurol. 2019;15(2):73-88.

The amyloid hypothesis of Alzheimer’s disease at 25 years.

Selkoe DJ, Hardy J. EMBO Mol Med. 2016;8(6):595-608.

Treatment of early AD subjects with BAN2401, an anti-Aβ protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline.

Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Dement. 2018;14(suppl 7):P1668-P1668.

Potential new approaches for diagnosis of Alzheimer’s disease and related dementias.

Turner RS, Stubbs T, Davies DA, Albensi BC. Front Neurol. 2020;11:496.

Related activities

Finding the Path in Alzheimer’s Disease

Early Diagnosis to Ongoing Collaborative Care

Faculty: Sharon Cohen, MD, FRCPC; R. Scott Turner, MD, PhD
Release: 11/20/2020
Expiration: 11/20/2021